Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
复制标题
DOI：
10.1128/aac.01643-08
复制
发表时间：
2009-07-01
影响因子：
4.9
通讯作者：
Rouzioux, Christine
中科院分区：
文献类型：
--
作者：
Delaugerre, Constance;Flandre, Philippe;Rouzioux, Christine
MONARK研究是一项初步随机试验，比较了洛匹那韦-利托那韦（LPV/r）单药治疗与LPV/r-齐多夫定-拉米夫定三联治疗对未经抗逆转录病毒治疗的人类免疫缺陷病毒1型（HIV-1）感染患者的安全性和疗效。在初始筛选时和病毒学失败时进行抗性测试（定义为包括具有>50和> 100的低水平病毒血症）。
The MONARK study was a pilot randomized trial comparing the safety and efficacy of lopinavir-ritonavir (LPV/r) monotherapy to those of LPV/r-zidovudine-lamivudine triple therapy for antiretroviral-naive human immunodeficiency virus type 1 (HIV-1)-infected patients. Resistance testing was performed at the time of initial screening and at the time of virological failure (defined to include low-level viremia with >50 and